Interviews

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study that examines the impact of physical activity, obesity, and smoking on bladder cancer mortality.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab for the treatment of cervical cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses the utility of Prostate Health Index (PHI).

Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses the results of a multisite randomized trial that examined continuing versus discontinuing statins in the setting of life-limiting illness.

Adam M. Brufsky, MD, PhD, gives a summary of his talk at the 13th Annual International Congress on the Future of Breast Cancer®. Brufsky discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses ESR1 mutations in primary breast cancer.

Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.

Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.

Walter J. Curran, Jr, MD, discusses a study that looked at radiation therapy with or without procarbazine, CCNU, and vincristine (PCV) for the treatment of low-grade glioma.

Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the tolerability and safety of sorafenib as seen in patients with thyroid cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the results of a randomized, double-blind, multicenter phase II trial that examined FOLFOX with or without ramucirumab as front-line therapy for advanced gastric or esophageal adenocarcinoma.

James A. Brown, MD, Professor of Urology, Professor of Biomedical Engineering, University of Iowa Carver College of Medicine, discusses an analysis of cell cycle progression scores in patients with clear cell renal cell carcinoma (ccRCC) to evaluate its prognostic value.

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III trial of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma.

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.

Graham Colditz, MD, DrPH, associate director, Prevention and Control, Alvin J. Siteman Cancer Center, discusses the need to focus on breast cancer prevention in low and middle income countries.

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Car, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, discusses the importance of companion diagnostics.

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).